Login / Signup

Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.

Marcel ReiserSteffen DörfelManfred HenselMark HoeslWolf-Oliver JordanMichael KoenigsmannDirk MeyerDietmar ReichertAndreas SchwarzerMoritz MarquardtKerstin KellershohnKathleen Jentsch-Ullrich
Published in: European journal of haematology (2018)
Chemoimmunotherapy with rituximab is feasible and safe in a wide variety of clinical settings in CLL, including the treatment of older patients with comorbidities (ClinicalTrials.gov NCT01178086).
Keyphrases
  • clinical practice
  • diffuse large b cell lymphoma
  • chronic lymphocytic leukemia
  • squamous cell carcinoma
  • locally advanced